Anticoagulation in Post MI LV Thrombus Trial in Nepal

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 196 participants.

Also called NCT05794399

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 196 participants (planned count) (from the registry)
Sponsor
Shahid Gangalal National Heart Centre (from the registry)
Registry
  • NCT NCT05794399
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Nepal (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05794399. Randomized; single masking; primary purpose treatment. Start 2023-06-19 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anticoagulation in Post MI LV Thrombus Trial in Nepal
Acronym
WaRMIN
Condition
Left Ventricular Thrombus
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Warfarin
Lead sponsor
Shahid Gangalal National Heart Centre (class: other)

Record details

Record id
cardio:ct-nct05794399
Content hash
2d9aae3a748c5b076a3f1b8a401c45ce00fd084539721c7c4db8034d1d95e3e4